<DOC>
	<DOCNO>NCT01912404</DOCNO>
	<brief_summary>The main purpose study test take study drug call emricasan ( also know IDN-6556 PF-03491390 ) affect overall patient survival one month treatment .</brief_summary>
	<brief_title>Study IDN-6556 Patients With Severe Alcoholic Hepatitis Contraindications Steroid Therapy</brief_title>
	<detailed_description>The study also see overall patient survival affect 6 month , study drug improve liver function .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<criteria>1 . Able provide write informed consent ( either patient patient 's legally acceptable representative ) , understand willing comply requirement study 2 . Male female patient 21 year age old 3 . Patients alcoholic hepatitis define : 1 . History heavy alcohol abuse use : &gt; 40 g/day female &gt; 60 g/day male day minimum period 6 month 2 . Consumed alcohol within 6 week entry study 3 . Biochemical parameter severe disease evidence MELD score &gt; 20 &lt; 35 , MELD score 3540 SOFA score &lt; 10 4 . Willingness utilize 2 reliable form contraception ( male females childbearing potential ) screen 1 month completion study treatment 5 . Patients establish contraindication steroid use include limited following : 1 . GI bleed 2 . Active infection , include spontaneous bacterial peritonitis , base positive blood culture , urine culture , chest xray ( positive , must antibiotics least 24 hour prior study entry ) 3 . Acute pancreatitis ( increased lipase &gt; 3x ULN radiologic evidence ) 4 . Positivity hepatitis B ( HBsAg+ ) C virus ( HCV+ ) , 5 . Renal failure 1 . Other concomitant cause liver disease result : 1 . Autoimmune liver disease ( positive antimitochondrial antibody smooth muscle antibody , positive reading antinuclear antibody titer &gt; 1:160 ) 2 . Metabolic liver disease ( abnormal ceruloplasmin level ) 3 . Vascular liver disease 4 . Drug induce liver disease Note : Concurrent viral hepatitis exclude . 2 . Coinfection human immunodeficiency virus ( HIV ) 3 . Sepsis evidence positive blood urine culture , pneumonia confirm xray 4 . History renal transplant and/or dialysis time entry study 5 . Inflammatory bowel disease 6 . Diagnosed suspected systemic lupus erythematosus ( SLE ) and/or rheumatoid arthritis ( RA ) 7 . Hepatocellular carcinoma ( HCC ) entry study 8 . Active nonliver malignancy curatively treat skin cancer ( basal cell squamous cell carcinoma ) 9 . Active tuberculosis chest xray study entry 10 . History presence clinically concern cardiac arrhythmia , prolongation screening ( pretreatment ) QT QTc interval &gt; 480 millisecond ( msec ) 11 . Significant systemic major illness liver disease , include coronary artery disease , cerebrovascular disease , pulmonary disease , renal failure , serious psychiatric disease , , opinion Investigator would preclude patient participate complete study 12 . Patients require use vasopressor inotropic support 13 . Liver biopsy , carry , show finding compatible alcoholic hepatitis 14 . Any patient receive investigational drug device within 30 day dose scheduled receive another investigational drug device course study Note : Investigational drug include drug use offlabel . 15 . If female , known pregnancy , positive urine serum pregnancy test , lactating/breastfeeding 16 . If male , partner know pregnant time entry study become pregnant patient study drug 1 month completion study drug 17 . Appropriate candidate corticosteroid therapy 18 . Treatment alcohol hepatitis within 1 month study entry use corticosteroid &gt; 1 week corticosteroid use time entry study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>alcoholic hepatitis</keyword>
</DOC>